Statistical approach for assessing the influence of calcium silicate and hpmc on the formulation of novel alfuzosin hydrochloride mucoadhesive-floating beads as gastroretentive drug delivery systems

AAPS PharmSciTech

Volumn 13, Issue 3, 2012, Pages 990-1004

  Fahmy, Rania Hassan ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

alfuzosin hydrochloride; calcium silicate; gastroretentive; mucoadhesive floating beads

Indexed keywords

ALFUZOSIN; CALCIUM SILICATE; HYDROXYPROPYLMETHYLCELLULOSE;

ADHESION; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; IN VITRO STUDY; INFRARED SPECTROSCOPY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; STATISTICAL ANALYSIS; TOPOGRAPHY;

ANIMALS; CALCIUM COMPOUNDS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL TRACT; MALE; METHYLCELLULOSE; QUINAZOLINES; RATS; SILICATES; TISSUE ADHESIVES;

EID: 84866096877     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9823-2     Document Type: Article

References (48)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991;338(8765):469-71.
2. Rossi C, Kortmann BB, Sonke GS, Floratos DL, Kiemeney LA, Wijkstra H, et al. alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. J Urol. 2001;165(1):38-41.
3. McVary KT. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. J Urol. 2006;175(1):35-42.
4. Guay DR. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004;2(1):14-23.
5. McKeage K, Plosker GL. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
6. Liu Q, Fassihi R. Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system. Int J Pharm. 2008;348(1-2):27-34.
7. Sweetman SC, editor. Martindale: the complete drug reference. London: Pharmaceutical Press; 2007. Electronic version.
8. Wilde MI, Fitton A, McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993;45(3):410-29.
9. Nair A, Gupta R, Vasanti S. In vitro controlled release of alfuzosin hydrochloride using HPMC-based matrix tablets and its comparison with marketed product. Pharm Dev Technol. 2007;12(6):621-5.
10. Kandi GS, Jain GK, Gupta A, Inventors; Sustained release composition of alfuzosin. United States patent US 2009/0028942 A1. Jan. 29, 2009.
11. Ali J, Arora S, Ahuja A, Babbar AK, Sharma RK, Khar RK, et al. Formulation and development of hydrodynamically balanced system for metformin: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2007;67(1):196-201.
12. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. J Control Release. 2005;107(2):300-9.
13. Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: a review. AAPS PharmSciTech. 2005;6(3):372-90.
14. Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol. 2006;6(5):501-8.
15. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63(3):235-59.
16. Gadad AP, Patil MB, Naduvinamani SN, Mastiholimath VS, Dandagi PM, Kulkarni AR. Sodium alginate polymeric floating beads for the delivery of cefpodoxime proxetil. J Appl Polym Sci. 2009;114:1921-6.
17. Javadzadeh Y, Hamedeyazdan S, Adibkia K, Kiafar F, Zarrintan MH, Barzegar-Jalali M. Evaluation of drug release kinetics and physico-chemical characteristics of metronidazole floating beads based on calcium silicate and gas-forming agents. Pharm Dev Technol. 2010;15(4):329-38.
18. Jain SK, Agrawal GP, Jain NK. A novel calcium silicate based microspheres of repaglinide: in vivo investigations. J Control Release. 2006;113(2):111-6.
19. Ishak RA, Awad GA, Mortada ND, Nour SA. Preparation, in vitro and in vivo evaluation of stomach-specific metronidazole-loaded alginate beads as local anti-Helicobacter pylori therapy. J Control Release. 2007;119(2):207-14.
20. Rajinikanth PS, Mishra B. Stomach-site specific drug delivery system of clarithromycin for eradication of Helicobacter pylori. Chem Pharm Bull. 2009;57(10):1068-75.
21. Jain AK, Jain SK, Yadav A, Agrawal GP. Controlled release calcium silicate based floating granular delivery system of ranitidine hydrochloride. Curr Drug Deliv. 2006;3(4):367-72.
22. Jain SK, Agrawal GP, Jain NK. In vitro evaluation of porous carrier-based floating granular delivery system of orlistat. PDA J Pharm Sci Technol. 2008;62(4):292-9.
23. Jain SK, Agrawal GP, Jain NK. Evaluation of porous carrier-based floating orlistat microspheres for gastric delivery. AAPS PharmSciTech. 2006;7(4):90.
24. Acarturk F, Takka S. Calcium alginate microparticles for oral administration: II. Effect of formulation factors on drug release and drug entrapment efficiency. J Microencapsul. 1999;16(3):291-301.
25. Takka S, Acarturk F. Calcium alginate microparticles for oral administration: I: Effect of sodium alginate type on drug release and drug entrapment efficiency. J Microencapsul. 1999;16(3):275-90.
26. Sharma S, Pawar A. Low density multiparticulate system for pulsatile release of meloxicam. Int J Pharm. 2006;313(1-2):150-8.
27. Srinatha A, Pandit JK. Multi-unit floating alginate system: effect of additives on ciprofloxacin release. Drug Deliv. 2008;15(7):471-6.
28. Ferreira Almeida P, Almeida AJ. Cross-linked alginate-gelatine beads: a new matrix for controlled release of pindolol. J Control Release. 2004;97(3):431-9.
29. Sahasathian T, Praphairaksit N, Muangsin N. Mucoadhesive and floating chitosan-coated alginate beads for the controlled gastric release of amoxicillin. Arch Pharm Res. 2010;33(6):889-99.
30. Shishu, Gupta N, Aggarwal N. Stomach-specific drug delivery of 5-fluorouracil using floating alginate beads. AAPS PharmSciTech. 2007;8(2): E143-9
31. Gattani SG, Savaliya PJ, Belgamwar VS. Floating-mucoadhesive beads of clarithromycin for the treatment of Helicobacter pylori infection. Chem Pharm Bull. 2010;58(6):782-7.
32. Moore JW, Flanner HH. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm Technol. 1996;20(6):64-74.
33. Rao KVR, Buri P. A novel in situ method to test polymers and coated microparticles for bioadhesion. Int J Pharm. 1989;52(3):265-70.
34. Ascentiis AD, deGrazia JL, Bowman CN, Colombo P, Peppas NA. Mucoadhesion of poly(2-hydroxyethyl methacrylate) is improved when linear poly(ethylene oxide) chains are added to the polymer network. J Control Release. 1995;33:197-201.
35. Hombach J, Bernkop-Schnürch A. Mucoadhesive drug delivery systems. In: Schäfer-Korting M, editor. Handbook of experimental pharmacology. Berlin Heidelberg: Springer; 2010.
36. Nakamura F, Ohtaa R, Machidab Y, Nagaic T. In vitro and in vivo nasal mucoadhesion of some water-soluble polymers. Int J Pharm. 1996;134(1-2):173-81.
37. Tadros MI. Controlled-release effervescent floating matrix tablets of ciprofloxacin hydrochloride: development, optimization and in vitro-in vivo evaluation in healthy human volunteers. Eur J Pharm Biopharm. 2010;74(2):332-9.
38. Waterman KC. A critical review of gastric retentive controlled drug delivery. Pharm Dev Technol. 2007;12(1):1-10.
39. Jain SK, Gupta A. Development of Gelucire 43/01 beads of metformin hydrochloride for floating delivery. AAPS PharmSciTech. 2009;10(4):1128-36.
40. Yuasa H, Takashima Y, Kanaya Y. Studies on the development of intragastric floating and sustained release preparation. I. Application of calcium silicate as a floating carrier. Chem Pharm Bull. 1996;44:1361-6.
41. Davis SS. Formulation strategies for absorption windows. Drug Discov Today. 2005;10(4):249-57.
42. McCauley JA, Brittain HG. Thermal methods of analysis. In: Brittain HG, editor. Physical characterization of pharmaceutical solids, drugs and pharmaceutical sciences. New York: Marcel Dekker; 1995. p. 223-50.
43. Moffat AC, Osselton MD, Widdop B, Galichet LY, editors. Clarke's analysis of drugs and poisons. London: Pharmaceutical Press; 2005.
44. Mura P, Faucci MT, Parrini PL. Effects of grinding with microcrystalline cellulose and cyclodextrins on the ketoprofen physicochemical properties. Drug Dev Ind Pharm. 2001;27(2):119-28.
45. Pattnaik S, Swain K, Choudhury P, Acharya PK, Mallick S. Alfuzosin hydrochloride transdermal films: evaluation of physicochemical, in vitro human cadaver skin permeation and thermodynamic parameters. Int Braz J Urol. 2009;35(6):716-29.
46. Mojumdar SC, Raki L. Characterization and properties of calcium silicate hydrates nanocomposites. 107th Annual Meeting, Exposition, and Technology Fair of the American Ceramic Society; 2005; Baltimore, D.C. 2005. p. 1-10.
47. Hsu CPS. Infrared spectroscopy. In: Settle FA, editor. Handbook of instrumental techniques for analytical chemistry. Upper Saddle River, NJ: Prentice Hall; 1997.
48. Li S, Lin S, Daggy BP, Mirchandani HL, Chien YW. Effect of HPMC and Carbopol on the release and floating properties of gastric floating drug delivery system using factorial design. Int J Pharm. 2003;253(1-2):13-22.